Bicycle Therapeutics plc (BCYC) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Bicycle Therapeutics (BCYC) PT Raised to $32 at Leerink Partners
October 31, 2024 1:10 PM EDTLeerink Partners analyst Jonathan Chang raised the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $32.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: BCYC reported 3Q24 financial results and provided a pipeline update in line with expectations. BCYC highlighted continued pipeline progress across the portfolio, including the Bicycle Toxin Conjugate (BTC) and Bicycle Radio Conjugate... More



